Case: 21-1262 Document: 64 Page: 1 Filed: 12/29/2021

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

SANOFI-AVENTIS U.S. LLC, SANOFI-AVENTIS DEUTSCHLAND GMBH, SANOFI WINTHROP INDUSTRIE, Plaintiffs-Appellants

v.

MYLAN GMBH, BIOCON LTD., BIOCON RESEARCH LTD., BIOCON SDN.BHD, BIOCON S.A., Defendants-Appellees ______________________

2021-1262 ______________________

Appeal from the United States District Court for the District of New Jersey in No. 2:17-cv-09105-SRC-CLW, Judge Stanley R. Chesler. ______________________

SUA SPONTE ______________________

Before DYK, CLEVENGER, and TARANTO, Circuit Judges. PER CURIAM. ORDER Case: 21-1262 Document: 64 Page: 2 Filed: 12/29/2021

2 SANOFI-AVENTIS U.S. LLC v. MYLAN GMBH

Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, Sanofi Winthrop Industrie (collectively, “Sanofi”) filed a patent infringement suit against Mylan GmbH, Bi- ocon Ltd., Biocon Research Ltd., Biocon Sdn.Bhd., and Bi- ocon S.A. (collectively, “Mylan”) in the District Court for the District of New Jersey asserting Mylan infringed claims 21, 22, 25, and 30 of Sanofi’s U.S. Patent No. 9,526,844 (“the ’844 Patent”). The district court found no infringement of the asserted claims and that the asserted claims are invalid for lack of written description. Sanofi ap- peals. We affirmed today in a related appeal, Sanofi-Aventis U.S. LLC, et al. v. Mylan GmbH, et al., No. 2020-2068, the final written decision by the U.S. Patent Trial and Appeal Board in IPR2018-01680 holding that claims 21–30 of the ’844 Patent would have been unpatentable as anticipated and/or obvious. Accordingly, Sanofi’s appeal from the dis- trict court’s ruling is moot. IT IS ORDERED THAT: Sanofi’s appeal in Appeal No. 2021-1262 is dismissed as moot.

FOR THE COURT

December 29, 2021 /s/ Peter R. Marksteiner Date Peter R. Marksteiner Clerk of Court